Clene Inc. is a clinical-stage pharmaceutical company developing therapeutics based on clean-surfaced nanotechnology (CSN). The company's primary focus is CNM-Au8, a gold nanoparticle therapeutic currently undergoing clinical evaluation across multiple indications. Completed Phase 2 trials have assessed CNM-Au8 in amyotrophic lateral sclerosis (ALS), chronic optic neuropathy with remyelination potential in multiple sclerosis, and Parkinson's disease. The company also investigates CNM-AgZn17, a gel polymer suspension of silver and zinc ions for infectious disease and wound healing applications, and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent.
Beyond clinical-stage programs, Clene markets dietary supplements including rMetx, an aqueous zinc-silver ion formulation, and KHC46, a low-concentration gold nanoparticle supplement. These consumer products represent a secondary revenue stream to support operations while core therapeutics progress through development.
Based in Salt Lake City, Utah, the company operates with approximately 75 full-time employees and maintains a market capitalization of $0.1 billion. As a clinical-stage entity, Clene has not achieved significant commercial-scale revenue from pharmaceutical products, with operations primarily supported through financing activities and limited dietary supplement sales.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | — | $-5.67 | -1106.4% | |
| 2023 | — | $-0.47 | -2.2% | |
| 2022 | — | $-0.46 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — |